Fair Value of Financial Instruments - Change In Fair Value, Contingent Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Change in fair value
Gain on partial extinguishment	$ (170,000)		$ (170,000)
Contingent Consideration Receivable | Discontinued Operations, Disposed of by Sale | Elusys Therapeutics
Change in fair value
Fair Value, Net Derivative Asset (Liability), Balance at the beginning			268,000
Issuance of convertible promissory note, related party, assets			(268,000)
Consideration Earn-out Receivable | Discontinued Operations, Disposed of by Sale | Elusys Therapeutics
Change in fair value
Fair Value, Net Derivative Asset (Liability), Balance at the beginning			1,720,000
Change in fair value			1,000,000
Fair Value, Net Derivative Asset (Liability), Balance at the ending	2,720,000		2,720,000
Consideration Earn-out Receivable | Elusys Therapeutics | Discontinued Operations, Disposed of by Sale
Change in fair value
Fair Value, Net Derivative Asset (Liability), Balance at the beginning	2,720,000
Fair Value, Net Derivative Asset (Liability), Balance at the ending	2,720,000		2,720,000
Contingent consideration | Pelican Therapeutics, Inc.
Change in fair value
Balance at the beginning		$ 11,234,114		$ 12,224,614
Change in fair value		1,100,000		109,500
Balance at the ending		$ 12,334,114		$ 12,334,114
Convertible and non-convertible promissory notes, related party
Change in fair value
Fair Value, Net Derivative Asset (Liability), Balance at the beginning	2,081,750
Gain on partial extinguishment	(170,000)		(170,000)
Change in fair value	18,250		114,250
Fair Value, Net Derivative Asset (Liability), Balance at the ending	2,680,000		2,680,000
Convertible promissory note, related party
Change in fair value
Issuance of convertible promissory note, related party, liabilities			1,985,750
Non-convertible promissory note, related party
Change in fair value
Issuance of convertible promissory note, related party, liabilities	$ 750,000		$ 750,000